Q-Line Biotech came to market through an SME IPO that opened on 21 May 2026 and closed on 25 May 2026, and the shares listed on 29 May 2026 on NSE SME. The price band was ₹326 to ₹343 per share and one lot was 400 shares, so the minimum application was ₹1,37,200. The issue size was ₹214.48 crore. The whole issue was fresh shares, so the money raised went to the company.
Purva Sharegistry (India) Pvt.Ltd was the registrar to the issue, and Hem Securities Ltd., Share India Capital Services Pvt.Ltd were the lead managers.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Founded in 2010, Q-Line Biotech Ltd. is involved in the development, manufacture and commercialization of various reagents (kits and POC devices) and consumables and manufacturing, importation, and supply of diagnostic instruments for different healthcare requirements. Q-Line Biotech Ltd. has been providing diagnostic instruments and IVD products for different healthcare requirements since 2013 either directly or via our distributor(s) primarily to diagnostic service organizations, hospitals, and medical colleges.
Q-Line Biotech Ltd.'s manufacturing categories comprise indigenous manufacture of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others (POC Devices & Rapid Tests) and supply/ manufacture of in vitro diagnostics (IVD), pathology equipment and devices. As of March 31, 2025, the company employed 313 permanent employees.
As described in the offer document.
| Metric | 31-Dec-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|
Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty, Abhay Agrawal.
Work out the listing gain for this SME IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Q-Line Biotech IPO was a ₹214.48 crore book-built issue, made up entirely of a fresh issue. It was priced at ₹326–₹343 per share with a lot size of 400 shares; the minimum retail application was 800 shares (₹2,74,400). The IPO was open from May 21 to May 25, 2026 and was subscribed 102.49x. Shares listed on NSE SME on May 29, 2026 at ₹452, a 31.8% premium to the issue price of ₹343. Purva Sharegistry (India) Pvt. Ltd.
is the registrar. Hem Securities Ltd. and Share India Capital Services Pvt. Ltd. are the book running lead managers.
The price band of Q-Line Biotech IPO is ₹326 to ₹343 per share.
The lot size of Q-Line Biotech IPO is 400 shares.
The minimum investment for Q-Line Biotech IPO is approximately ₹2,74,400 based on the upper price band.
The allotment date of Q-Line Biotech IPO is May 26, 2026.
Q-Line Biotech IPO's final recorded GMP before listing was ₹110 per share (a 32% premium over the ₹343 upper price band). The shares listed at ₹452. GMP is unofficial and does not forecast or guarantee the actual listing price.
You can check Q-Line Biotech IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Q-Line Biotech IPO allotment status on Rupix for quick and easy access.
₹326 to ₹343 per share, against a face value of ₹10. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 400 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹1,37,200. After listing, SME shares also trade in lots rather than one share at a time.
₹1,37,200, for one lot of 400 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 21 May 2026 and closed on 25 May 2026.
The basis of allotment was published on 26 May 2026 by Purva Sharegistry (India) Pvt.Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 29 May 2026 on NSE SME.
The issue size was ₹214.48 crore. The fresh issue was 62,53,200 shares (aggregating up to ₹214.48 crore).